{"EVIDENCE": {"type": "evidence", "assertions": [{"type": "assertion", "description": "MPL encodes the thrombopoietin receptor, an important growth and survival factor for megakaryocytes. Somatic activating mutation in MPL (W515L, W515K) has been reported in approximately 1%-10% of cases of JAK2 V617F-negative myelofibrosis, essential thrombocythemia, a subset of cases of acute megakaryoblastic leukemia and has been associated with sensitivity to JAK inhibitors. The W515 mutations are typically not observed in polycythemia vera or other myeloid disorders (chronic myelomonocytic leukemia, myelodysplastic syndrome). A S505N activating mutation has also been described in familial essential thrombocythemia.  MPL mutation is  included as one of the major diagnostic criteria for primary myelofibrosis and essential thrombocythemia in the 2016 revision of the WHO classification.", "gene": {"name": "MPL"}, "variants": [{"name": "MPL codon(s) 515 missense"}, {"name": "MPL W515L"}, {"name": "MPL W515K"}], "tier": 1, "tumor_types": ["Myeloproliferative Neoplasm", "Essential Thrombocythemia", "Primary Myelofibrosis", "Acute Leukemia of Unspecified Cell Type", "Acute Myeloid Leukemia", "Anemia, Unspecified", "Atypical Chronic Myeloid Leukemia", "B Lymphoblastic Leukemia/Lymphoma", "Chronic Myeloid Leukemia", "Chronic Myelomonocytic Leukemia", "Chronic Neutrophilic Leukemia", "Cytopenia", "Eosinophilia", "Histiocytic and Dendritic Cell Neoplasms", "Langerhans Cell Histiocytosis", "Leukocytosis", "Leukopenia", "Mast Cell Neoplasm", "MDS with Ring Sideroblasts", "Monocytosis", "Myelodysplastic Syndrome", "Myelodysplastic/Myeloproliferative Neoplasm", "Myeloid Neoplasm", "Other Acute Leukemia", "Polycythemia Vera", "Polycythemia", "T Lymphoblastic Leukemia/Lymphoma", "Thrombocytopenia, Unspecified", "Thrombocytosis"], "tissue_types": ["Blood", "Bone Marrow"]}], "source": {"citations": ["Pikman Y, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3(7):e270", "Ding J, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 2004;103(11):4198-200", "Pardanani AD, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006;108(10):3472-6", "Hussein K, et al. MPLW515L mutation in acute megakaryoblastic leukaemia. Leukemia 2009;23(5):852-5", "Vannucchi AM, et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013;27(9):1861-9", "Rumi E, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2014;123(10):1544-51", "Arber DA, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127(20):2391-405"]}}, "GENE": {"type": "gene", "name": "MPL", "variants": [{"name": "MPL S505N", "evidence_count": 1}, {"name": "MPL codon(s) 515 missense", "evidence_count": 1}, {"name": "MPL W515L", "evidence_count": 1}, {"name": "MPL Y591D", "evidence_count": 1}, {"name": "MPL W515K", "evidence_count": 1}]}, "VARIANTS": [{"type": "variant", "name": "MPL W515K", "gene": "MPL", "evidence": {"type": "evidence", "sources": ["Pikman Y, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3(7):e270", "Ding J, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 2004;103(11):4198-200", "Pardanani AD, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006;108(10):3472-6", "Hussein K, et al. MPLW515L mutation in acute megakaryoblastic leukaemia. Leukemia 2009;23(5):852-5", "Vannucchi AM, et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013;27(9):1861-9", "Rumi E, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2014;123(10):1544-51", "Arber DA, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127(20):2391-405"]}, "assertions": [{"type": "assertion", "description": "MPL encodes the thrombopoietin receptor, an important growth and survival factor for megakaryocytes. Somatic activating mutation in MPL (W515L, W515K) has been reported in approximately 1%-10% of cases of JAK2 V617F-negative myelofibrosis, essential thrombocythemia, a subset of cases of acute megakaryoblastic leukemia and has been associated with sensitivity to JAK inhibitors. The W515 mutations are typically not observed in polycythemia vera or other myeloid disorders (chronic myelomonocytic leukemia, myelodysplastic syndrome). A S505N activating mutation has also been described in familial essential thrombocythemia.  MPL mutation is  included as one of the major diagnostic criteria for primary myelofibrosis and essential thrombocythemia in the 2016 revision of the WHO classification.", "tumor_types": ["Myeloproliferative Neoplasm", "Essential Thrombocythemia", "Primary Myelofibrosis", "Acute Leukemia of Unspecified Cell Type", "Acute Myeloid Leukemia", "Anemia, Unspecified", "Atypical Chronic Myeloid Leukemia", "B Lymphoblastic Leukemia/Lymphoma", "Chronic Myeloid Leukemia", "Chronic Myelomonocytic Leukemia", "Chronic Neutrophilic Leukemia", "Cytopenia", "Eosinophilia", "Histiocytic and Dendritic Cell Neoplasms", "Langerhans Cell Histiocytosis", "Leukocytosis", "Leukopenia", "Mast Cell Neoplasm", "MDS with Ring Sideroblasts", "Monocytosis", "Myelodysplastic Syndrome", "Myelodysplastic/Myeloproliferative Neoplasm", "Myeloid Neoplasm", "Other Acute Leukemia", "Polycythemia Vera", "Polycythemia", "T Lymphoblastic Leukemia/Lymphoma", "Thrombocytopenia, Unspecified", "Thrombocytosis"], "tissue_types": ["Blood", "Bone Marrow"], "tier": 1, "gene": "MPL"}]}, {"type": "variant", "name": "MPL W515L", "gene": "MPL", "evidence": {"type": "evidence", "sources": ["Pikman Y, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3(7):e270", "Ding J, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 2004;103(11):4198-200", "Pardanani AD, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006;108(10):3472-6", "Hussein K, et al. MPLW515L mutation in acute megakaryoblastic leukaemia. Leukemia 2009;23(5):852-5", "Vannucchi AM, et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013;27(9):1861-9", "Rumi E, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2014;123(10):1544-51", "Arber DA, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127(20):2391-405"]}, "assertions": [{"type": "assertion", "description": "MPL encodes the thrombopoietin receptor, an important growth and survival factor for megakaryocytes. Somatic activating mutation in MPL (W515L, W515K) has been reported in approximately 1%-10% of cases of JAK2 V617F-negative myelofibrosis, essential thrombocythemia, a subset of cases of acute megakaryoblastic leukemia and has been associated with sensitivity to JAK inhibitors. The W515 mutations are typically not observed in polycythemia vera or other myeloid disorders (chronic myelomonocytic leukemia, myelodysplastic syndrome). A S505N activating mutation has also been described in familial essential thrombocythemia.  MPL mutation is  included as one of the major diagnostic criteria for primary myelofibrosis and essential thrombocythemia in the 2016 revision of the WHO classification.", "tumor_types": ["Myeloproliferative Neoplasm", "Essential Thrombocythemia", "Primary Myelofibrosis", "Acute Leukemia of Unspecified Cell Type", "Acute Myeloid Leukemia", "Anemia, Unspecified", "Atypical Chronic Myeloid Leukemia", "B Lymphoblastic Leukemia/Lymphoma", "Chronic Myeloid Leukemia", "Chronic Myelomonocytic Leukemia", "Chronic Neutrophilic Leukemia", "Cytopenia", "Eosinophilia", "Histiocytic and Dendritic Cell Neoplasms", "Langerhans Cell Histiocytosis", "Leukocytosis", "Leukopenia", "Mast Cell Neoplasm", "MDS with Ring Sideroblasts", "Monocytosis", "Myelodysplastic Syndrome", "Myelodysplastic/Myeloproliferative Neoplasm", "Myeloid Neoplasm", "Other Acute Leukemia", "Polycythemia Vera", "Polycythemia", "T Lymphoblastic Leukemia/Lymphoma", "Thrombocytopenia, Unspecified", "Thrombocytosis"], "tissue_types": ["Blood", "Bone Marrow"], "tier": 1, "gene": "MPL"}]}, {"type": "variant", "name": "MPL codon(s) 515 missense", "gene": "MPL", "evidence": {"type": "evidence", "sources": ["Pikman Y, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3(7):e270", "Ding J, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 2004;103(11):4198-200", "Pardanani AD, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006;108(10):3472-6", "Hussein K, et al. MPLW515L mutation in acute megakaryoblastic leukaemia. Leukemia 2009;23(5):852-5", "Vannucchi AM, et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013;27(9):1861-9", "Rumi E, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2014;123(10):1544-51", "Arber DA, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127(20):2391-405"]}, "assertions": [{"type": "assertion", "description": "MPL encodes the thrombopoietin receptor, an important growth and survival factor for megakaryocytes. Somatic activating mutation in MPL (W515L, W515K) has been reported in approximately 1%-10% of cases of JAK2 V617F-negative myelofibrosis, essential thrombocythemia, a subset of cases of acute megakaryoblastic leukemia and has been associated with sensitivity to JAK inhibitors. The W515 mutations are typically not observed in polycythemia vera or other myeloid disorders (chronic myelomonocytic leukemia, myelodysplastic syndrome). A S505N activating mutation has also been described in familial essential thrombocythemia.  MPL mutation is  included as one of the major diagnostic criteria for primary myelofibrosis and essential thrombocythemia in the 2016 revision of the WHO classification.", "tumor_types": ["Myeloproliferative Neoplasm", "Essential Thrombocythemia", "Primary Myelofibrosis", "Acute Leukemia of Unspecified Cell Type", "Acute Myeloid Leukemia", "Anemia, Unspecified", "Atypical Chronic Myeloid Leukemia", "B Lymphoblastic Leukemia/Lymphoma", "Chronic Myeloid Leukemia", "Chronic Myelomonocytic Leukemia", "Chronic Neutrophilic Leukemia", "Cytopenia", "Eosinophilia", "Histiocytic and Dendritic Cell Neoplasms", "Langerhans Cell Histiocytosis", "Leukocytosis", "Leukopenia", "Mast Cell Neoplasm", "MDS with Ring Sideroblasts", "Monocytosis", "Myelodysplastic Syndrome", "Myelodysplastic/Myeloproliferative Neoplasm", "Myeloid Neoplasm", "Other Acute Leukemia", "Polycythemia Vera", "Polycythemia", "T Lymphoblastic Leukemia/Lymphoma", "Thrombocytopenia, Unspecified", "Thrombocytosis"], "tissue_types": ["Blood", "Bone Marrow"], "tier": 1, "gene": "MPL"}]}], "ASSERTION": {"type": "assertion", "description": "MPL encodes the thrombopoietin receptor, an important growth and survival factor for megakaryocytes. Somatic activating mutation in MPL (W515L, W515K) has been reported in approximately 1%-10% of cases of JAK2 V617F-negative myelofibrosis, essential thrombocythemia, a subset of cases of acute megakaryoblastic leukemia and has been associated with sensitivity to JAK inhibitors. The W515 mutations are typically not observed in polycythemia vera or other myeloid disorders (chronic myelomonocytic leukemia, myelodysplastic syndrome). A S505N activating mutation has also been described in familial essential thrombocythemia.  MPL mutation is  included as one of the major diagnostic criteria for primary myelofibrosis and essential thrombocythemia in the 2016 revision of the WHO classification.", "gene": {"name": "MPL"}, "variants": [{"name": "MPL codon(s) 515 missense"}, {"name": "MPL W515L"}, {"name": "MPL W515K"}], "tier": 1, "tumor_types": ["Myeloproliferative Neoplasm", "Essential Thrombocythemia", "Primary Myelofibrosis", "Acute Leukemia of Unspecified Cell Type", "Acute Myeloid Leukemia", "Anemia, Unspecified", "Atypical Chronic Myeloid Leukemia", "B Lymphoblastic Leukemia/Lymphoma", "Chronic Myeloid Leukemia", "Chronic Myelomonocytic Leukemia", "Chronic Neutrophilic Leukemia", "Cytopenia", "Eosinophilia", "Histiocytic and Dendritic Cell Neoplasms", "Langerhans Cell Histiocytosis", "Leukocytosis", "Leukopenia", "Mast Cell Neoplasm", "MDS with Ring Sideroblasts", "Monocytosis", "Myelodysplastic Syndrome", "Myelodysplastic/Myeloproliferative Neoplasm", "Myeloid Neoplasm", "Other Acute Leukemia", "Polycythemia Vera", "Polycythemia", "T Lymphoblastic Leukemia/Lymphoma", "Thrombocytopenia, Unspecified", "Thrombocytosis"], "tissue_types": ["Blood", "Bone Marrow"]}}